Supplemental Online Content

Hess CN, Szarek M, Anand SS, et al. Rivaroxaban and risk of venous thromboembolism in patients with symptomatic peripheral artery disease after lower extremity revascularization. *JAMA Netw Open*. 2022;5(6):e2215580. doi:10.1001/jamanetworkopen.2022.15580

eTable. Candidate Variables for Factors Associated With VTE

This supplemental material has been provided by the authors to give readers additional information about their work.
**eTable. Candidate Variables for Factors Associated With VTE**

| Variable                                      |
|-----------------------------------------------|
| Age >=75                                       |
| Sex                                           |
| White race                                    |
| Hispanic/latino ethnicity                     |
| Current smoker                                 |
| History of diabetes                           |
| History of hypertension                       |
| History of hyperlipidemia                     |
| History of HF                                 |
| eGFR <60                                      |
| Weight >=60 kg                                |
| History of COPD                               |
| Polyvascular disease                          |
| Prior endovascular revascularization          |
| Prior surgical revascularization              |
| Prior amputation                              |
| History of malignancy                         |
| Index ankle-brachial index                    |
| Index revascularization type                  |
| Indication for index revascularization        |
| (claudication vs critical limb ischemia)      |
| Statin at baseline                            |
| Clopidogrel at baseline                       |
| Rivaroxaban treatment                         |